Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

NCT02057640 is registered in ClinicalTrials.gov with Jason Valent as lead sponsor.

NCT NCT02057640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02057640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Jason Valent
Phase
Phase 1/2
Overall status
Completed
Start date
May 22, 2014
Completion date
May 15, 2018
Enrollment
16 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

kahler disease, multiple myeloma, myelomatosis, plasma-cell myeloma